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T h e  C  term in u s o f th e  c a ta ly tic  y-su b u n it o f p h o sp h o ­
ry la se  k in a se  co m p rises a  re g u la to ry  d o m ain  th a t co n ­
ta in s re g io n s im p o rta n t fo r  su b u n it in te ractio n s an d  
au to in h ib ito ry  fu n ctio n s. M o n o sp e cific  an tib o d ies  
ra ise d  a g a in st fo u r sy n th e tic  p ep tid e s fro m  th is reg io n , 
P h K l (3 6 2 - 3 8 6 ), P h K 5  (3 4 2 - 3 6 6 ), P h K 9  (3 2 2 - 3 4 6 ), an d  
P h K 13  (3 0 2 - 3 2 6 ), w e re  fo u n d  to h a v e  s ig n ifica n t effects  
on  th e c a ta ly tic  a c tiv itie s  o f p h o sp h o ry la se  k in a se  hol- 
o en zym e an d  th e y 8  com p lex. A n tib o d ie s ra ise d  a g a in st  
th e v e r y  C  term in u s o f th e y-su b u n it, a n ti-P h K l an d  
a n ti-P h K 5 , m a rk e d ly  a c tiv a te d  b o th  h olo en zym e a n d  th e  
y 8  com p lex, in  th e p re se n ce  a n d  ab se n ce  o f C a 2+ . In  th e  
p re se n ce  o f C a 2+ a t p H  8 .2 , a n ti-P h K l a c tiv a te d  th e  h o l­
o en zym e m o re th a n  11-fo ld  a n d  a c tiv a te d  th e y-8 com ­
p le x  2 .5 -fold. A c tiv a tio n  o f  th e  h olo en zym e an d  th e y 8  
co m p lex b y  a n ti-P h K 5  w a s  5 0 - 70 %  o f th a t o b se rv e d  w ith  
a n ti-P h K l. P r io r  p h o sp h o ry la tio n  o f  th e h olo en zym e b y  
th e cA M P -d e p e n d e n t p ro te in  k in a se  b lo ck ed  a c tiv a tio n  
b y  b o th  a n ti-P h K l an d  a n ti-P h K 5 . A n tib o d ie s ra ise d  
a g a in st th e  p ep tid e s fro m  th e N  term in u s o f th e re g u la ­
to ry  dom ain , a n ti-P h K 9  an d  a n ti-P h K 13 , w e re  in h ib i­
to ry, w ith  th e ir g re a te st e ffects on  th e y-8 com plex. 
T h ese  d a ta  d em o n strate  th a t th e b in d in g  o f  an tib o d ies  
to sp e cific  re g io n s w ith in  th e  re g u la to ry  d o m ain  o f the  
y -su b u n it c a n  au g m en t o r  in h ib it stru c tu ra l ch a n ge s  
a n d  su b u n it in te ractio n s im p o rta n t in  re g u la tin g  phos- 
p h o ry la se  k in a se  a c tiv ity .
Phosphory lase k inase  (A TP:phosphorylase phospho trans­
ferase, EC 2.7.1.38) catalyzes th e  conversion of phosphorylase b 
to a  and  p lays a  key role in  reg u la tin g  glycogen breakdow n in 
response to adrenergic an d  neu rona l stim uli. The skele ta l m u s­
cle isozyme is a  m ultim eric  enzym e w ith  the  su b u n it composi­
tion  (a fiy 8)4 an d  a  m olecular w eight of 1.3 X 106 (review ed in 
Ref. 1). The a-, 0-, and  S-subunits are  regu la to ry  subun its , 
w hereas th e  7 -subun it is th e  cataly tic su bun it (2). In terac tions 
of th e  regu la to ry  subun its  w ith  the  7-subun it serve to m odulate 
the  activ ity  of th e  enzym e in  response to th e  second m essen­
gers, cAMP and  C a2+. P hosphory lation  of th e  a- and  0-subun its
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by th e  cA M P-dependent p ro te in  k inase  an d  by au tophospho­
ry la tion  ac tiva tes th e  enzym e a t pH  6 .8 . The unphosphory lated  
a- and  0-subun its  a re  th o u g h t to in h ib it th e  cataly tic site from 
exhib iting  m axim um  catalytic po ten tia l, since inh ib ition  can be 
relieved by increasing  pH  to 8.2, by phosphorylation , by p ro te­
olysis, or by dissociation of these  su b u n its  from  th e  holoenzym e 
complex. C a2+ dependence is conferred upon th e  enzym e by th e  
S-subunit, w hich is iden tical to calm odulin (3).
R esidues 19 -276  of th e  7-subun it rep re sen t the  catalytic 
dom ain of th e  enzym e based  on sequence homology w ith  o ther 
p ro te in  k inases (2). Two crystal s tru c tu res  of a constitu tively  
active catalytic core of th e  7 -subun it (residues 1-298) have 
recen tly  been  solved to a  reso lu tion  of 3.0 A or b e tte r  (4). 
o v e ra ll, these  two 7-subun it s tru c tu re s  are  very sim ilar to th e  
catalytic cores of o ther p ro te in  k inases. The C -term inal 110 
am ino acids of th e  7-subun it (277-386) are  th o u g h t to contain 
pseudosubstra te /au to inh ib ito ry  dom ains and  su b u n it in te rac ­
tion  dom ains based  on th is  region’s lack  of sequence sim ilarity  
to o ther p ro te in  k inases (2 ) and  s tud ies involving lim ited  pro­
teolysis (5) and  site-d irected  m u tagenesis (6 - 8 ). By using  a 
lib ra ry  of overlapping synthetic  7-subun it peptides, the  regions 
corresponding to 7302-326  an d  7342-366  have been  identified  
as being regu la to ry  subdom ains th a t  act in  concert to m ediate  
in te rac tions betw een  th e  7-subun it and  th e  cataly tic dom ain of 
th e  7 -subun it (6 , 9, 10). P ep tides corresponding to these  two 
regions (term ed  PhK 13 and  PhK 5, respectively) b ind  calm od­
u lin  w ith  h igh  affinity  (9) and  com petitively in h ib it phospho- 
ry lase k inase  cataly tic activ ity  (6 , 10). S ite-d irected  m u tag en ­
esis experim en ts (6) and  sm all-angle sca tte rin g  stud ies (1 1 ) 
have provided lim ited  s tru c tu ra l in form ation  regard ing  the 
in te rac tions of PhK 5 and  PhK 13 w ith  th e  7-subun it catalytic 
dom ain (6) and  th e  S-subunit (11). However, de ta iled  in form a­
tion  regard ing  th e  s tru c tu re  of the  7 -subun it regu la to ry  dom ain 
is no t p resen tly  available. I t  h as  also been  proposed th a t  the 
regu la to ry  dom ain of the  7 -subun it m igh t in te rac t directly  w ith  
th e  a- and  0-subun its  (2 ), b u t th e  sites of in te rac tion  on the 
7-subun it for the  a- an d  0 -subun its  have ye t to be firm ly 
estab lished .
The p resen t investiga tion  w as u n d e rtak en  to b e tte r  define 
th e  po ten tia l regu la to ry  functions of specific regions w ith in  the 
regu la to ry  dom ain of th e  7 -subun it of phosphorylase k inase. 
A ntibodies w ere ra ised  ag a in s t each of four peptides, PhK 1 
(7362-386), PhK 5 (7342-366), PhK 9 (7322-346), and  PhK13 
(7302-326), th a t  together span  th e  C -term inal 85 am ino acids 
of th e  7-subun it (Fig. 1). These monospecific antibodies w ere 
th e n  affin ity-purified  an d  assayed  for th e ir  ab ility  to ac tiva te  or 
in h ib it th e  cataly tic activ ity  of several d ifferen t form s of phos- 
phorylase k inase. The approach  of using  an tipep tide  antibodies 
as probes to assess th e  functional p roperties of p u ta tiv e  regu ­






















Fig. 1. N om encla ture of syn thetic  y -subunit (PhK) pep tides 
used  for ra is in g  m onospecific an tise ra . Each peptide also carries a 
C-terminal Gly-amide residue, which is not shown.
used  to characterize  th e  calm odulin-binding dom ain of rab b it 
skele ta l m uscle m yosin ligh t chain  k inase  (1 2 ), th e  pseudosub­
s tra te  dom ain of p ro te in  k inase  C (13), and  po ten tia l regu la to ry  
dom ains in  casein k inase  II (14), th e  insu lin -like grow th fac- 
tor-I recep to r k inase  (15, 16), and  rhodopsin  k inase  (17). The 
re su lts  of th e  stud ies p resen ted  here  ind icate  th a t  b ind ing  of 
monospecific an tibodies to th e  regu la to ry  dom ain of th e  y-sub- 
u n it can have profound effects on cata ly tic activ ity  and  provide 
im p o rtan t in s igh ts  into s tru c tu ra l fea tu res  involved in  reg u la ­
tory in te rac tions in  th e  phosphorylase k in ase  holoenzym e 
complex.
EXPERIMENTAL PROCEDURES
Preparation o f Phosphorylase b, Phosphorylase Kinase Holoenzyme, 
and S y  Complex—Phosphorylase kinase holoenzyme was prepared by 
the procedure of Cohen (18), and phosphorylase b was prepared using 
the procedure of Fischer and Krebs (19). Protein concentrations were 
determined spectrophotometrically using values of E 2%0nm of 12.4 (18) 
and 13.2 (20) for phosphorylase kinase and phosphorylase b, respec­
tively. The y-subunit of phosphorylase kinase was purified using re- 
versed-phase HPLC1 as described by Crabb and Heilmeyer (21), except 
tha t a Vydac C-4 analytical column (5 mm, 0.46 X 25 cm) was used 
instead of a Vydac C-18 column. The subunit elution pattern obtained 
using the C-4 column was similar to tha t reported for the C-18 column. 
The active S y  complex was prepared from HPLC-purified y-subunit 
using the reactivation procedure described by Kee and Graves (22). The 
reactivation buffer contained 50 mM Tris, 50 mM ^-glycerophosphate, 
pH 8.0, 2 mM dithiothreitol, 0.1 mM CaCl2, 3 mM calmodulin, 1 mg/ml 
bovine serum albumin, and HPLC-purified y-subunit (diluted 10-fold 
into the reactivation buffer). Reactivation was carried out a t 0 °C for
18 h.
Peptide Synthesis—Synthesis ofpeptides was done by standard solid- 
phase techniques using t -butoxycarbonyl chemistry as described previ­
ously (9). Peptide purification was performed using reversed-phase 
HPLC, and each sequence was confirmed by amino acid analysis and 
protein sequence analysis.
Antibody Production and Purification—Monospecific polyclonal an­
tibodies were raised in rabbits against the synthetic peptides PhK1 
(y362—386), PhK5 (y342-366), PhK9 (y322-346), and PhK13 (y302- 
326), which span the C-terminal 85 residues of the y-subunit (see Fig. 
1). In the case of PhK1, PhK5, and PhK9, the peptides were coupled to 
keyhole limpet hemocyanin using glutaraldehyde, and then each pep­
tide was used to immunize two rabbits using the Ribi Adjuvant System 
(Hamilton, MT). Booster injections were given on days 14 and 28 and 
every month thereafter. Rabbits were bled each week (3 times a month) 
between immunizations. In the case of PhK13, the peptide was coupled 
to Imject maleimide-activated keyhole limpet hemocyanin (Pierce) and 
used to immunize two rabbits. These rabbits were immunized and bled 
by Bethyl Laboratories (Montgomery, TX) according to their recom­
mended schedule. Initial screening using an enzyme-linked immu­
nosorbent assay (ELISA) was performed to select the rabbits giving the 
best responses and the bleeds with the highest titer against phospho- 
rylase kinase holoenzyme. These antisera were used for the subsequent 
workup described below.
1 The abbreviations used are: HPLC, high performance liquid chro­
matography; MOPS, 4-morpholinepropanesulfonic acid; ELISA, en­
zyme-linked immunosorbent assay.
Each antiserum was subjected to the following prepurification pro­
cedure to remove contaminating lipids and lipoproteins. To each milli­
liter of antiserum, 0.05 ml 5% (w:v) sodium dextran sulfate (Pharmacia 
Biotech Inc.) was added, stirred, then allowed to sit on ice for 1 h. To 
this solution was added 0.09 ml of 11.1% (w/v) CaC^/ml of antiserum. 
The solution was allowed to settle on ice for 1—2 h, and the precipitate 
was removed by centrifugation a t 5000 X g  for 20 min. To further purify 
the antipeptide antibodies, the supernatant was subjected to ammo­
nium sulfate fractionation by slowly adding, while stirring, 0.667 ml of 
saturated ammonium sulfate (pH 7.3)/ml of antibody solution. The 
solution was allowed to stir for 1  h on ice and then was centrifuged at 
5000 X g  for 25 min. The precipitated pellet was resuspended in a 
minimal volume of Milli-Q water and then dialyzed overnight against 
Milli-Q water at 4°C. The dialysate was then subjected to affinity 
purification using phosphorylase kinase immobilized to Sepharose 4B.
Phosphorylase kinase holoenzyme was immobilized on CNBr-acti- 
vated Sepharose 4B at a density of 5 mg of protein/ml of gel to produce 
affinity columns for the isolation of each of the antipeptide antibodies. 
Dry CNBr-activated Sepharose (1.14 g; Sigma) was suspended in 1 mM 
HCl to dissolve stabilizers and hydrate the gel. After about 1 min, the 
suspension was filtered, and to the moist gel was added 20 mg of 
phosphorylase kinase dissolved in 0.1m borate, 0.5 M NaCl, pH 8.3. The 
gel and phosphorylase kinase were gently shaken for 24 h a t 4 °C, after 
which the suspension was mixed with 1 M ethanolamine and shaken at 
room temperature for another 2 h to block unreacted sites on the gel. 
The gel was washed with 0.1 M borate, 0.5 M NaCl, pH 8.3, followed by
0.1 M acetic acid, 0.5 M NaCl, pH 4.0, and was then aliquoted into four 
1-ml columns. The columns were stored in 50 mM MOPS, 2 mM EDTA, 
pH 7.0, a t 4 °C. Before use, the columns used for purification of anti- 
PhK1 and anti-PhK5 were equilibrated with buffer containing 50 mM 
MOPS, pH 7.0, 1 mM dithiothreitol, and 1 /xM leupeptin. The columns 
used for anti-PhK9 and anti-PhK13 were preequilibrated with the 
above buffer containing 200 xM CaC^. Antipeptide antibodies were 
applied to the columns in the presence (anti-PhK9 and anti-PhK13) or 
absence (anti-PhK1 and anti-PhK5) of 200 xM Ca2+. The columns were 
then washed with equilibration buffer until the A280 of the column 
effluent was less than 0.05. The anti-PhK1 and anti-PhK5 antibodies 
were eluted with 500 mM MgCl2, and the anti-PhK9 and anti-PhK13 
antibodies were eluted with 50 mM MOPS, pH 7.0, 1 mM dithiothreitol, 
1 xM leupeptin, and 2 mM EDTA. Eluates were desalted using Bio-Gel 
P6 DG (Bio-Rad) desalting columns and stored in phosphate-buffered 
saline a t 4 °C. Antibody concentrations were determined spectrophoto­
metrically using a E2%q nm value of 15 for IgG (23).
Fab fragments were prepared from affinity-purified anti-PhK1 anti­
body according to the procedure ofGibson et al. (24) as briefly described 
here. A sample of affinity-purified antibody (0.5 mg) was dialyzed 
overnight at pH 7.5 against 50 mM Tris-HCl, 0.15 M NaCl, and 2 mM 
EDTA. After dialysis, dithioerythritol was added to a final concentra­
tion of 1 mM. A suspension of mercuripapain (Sigma) was prepared in 
the above buffer in the presence of 10 mM dithioerythritol. The solutions 
of protease and antibody were mixed in a ratio of 1:33 (w:w) and 
incubated a t 37 °C for 30 min. The reaction was stopped by the addition 
of dehydroascorbic acid to a final concentration of 1 mM, and the solu­
tion was allowed to sit for 15 min. The solution was filtered (0.22-xm 
filter, Pharmacia), and the Fab fragments were separated by fast pro­
tein liquid chromatography using a Superdex 200 prep grade (HiLoad 
16/60) column.
A sandwich ELISA method was used to determine the ability of 
anti-PhK1 Fab fragments to bind phosphorylase kinase and the yS  
complex. The procedure used the reagents and protocol provided in the 
ELISAmate kit (Kirkegaard and Perry Laboratories). Polystyrene mi­
crotiter plates (96-well flat-bottom, Corning) were first coated with the 
indicated concentrations of anti-PhK1 or anti-PhK1 Fab fragment for
1 h at room temperature. Either phosphorylase kinase holoenzyme (0.9 
xg/ml) or y 8 complex in 1 % (w/w) bovine serum albumin was then 
added and allowed to bind for 1  h before the plate was emptied and 
rinsed with 1% bovine serum albumin. Antibody raised against a syn­
thetic multiple antigen peptide corresponding to the N terminus of the 
y-subunit, GKSHSGPLAADRT, was then added (0.7 xg/ml in 1% bovine 
serum albumin) and allowed to bind for 1 h. The plate was then emptied 
and washed three times with 0.02% Tween 20 (v/v). Peroxidase-labeled 
goat anti-rabbit IgG (0.3 xg/ml in 1% bovine serum albumin) was added 
and incubated for 1 h. The plate was then washed three times (0.02% 
Tween 20) before adding the color development reagents, 3,3',5,5'- 
tetramethylbenzidine and hydrogen peroxide. The plate was read in 
kinetic mode on a UVmax microplate reader (Molecular Devices) a t 650 
nm using SOFTmax (version 2.01) for data acquisition and analysis.
























Fig. 2. Effect o f overn igh t incuba tion  w ith  affin ity -purified  
an tip ep tid e  an tibod ies on phosphory lase k inase  holoenzym e 
activ ity . Phosphorylase kinase holoenzyme was assayed at pH 8.2 in 
the presence of antipeptide antibodies as described under “Experimen­
ta l Procedures.” The horizontal dashed line at 100% represents the 
Ca2+-stimulated activity in the absence of antibody. Error bars repre­
sent the standard error of the mean. *, not determined.
protein kinase assay was used to monitor antipeptide antibody inter­
actions with phosphorylase kinase holoenzyme and the y-S complex. 
Enzymatic activities of the holoenzyme and the y S  complex were de­
termined by measuring the rate of 32P incorporation from [y-32P]ATP 
into phosphorylase b or a synthetic peptide substrate (SDQEKRKQiS- 
VRGLG). The reaction mixture (50 ^l) contained 50 mM HEPES, 42 mM 
Tris, 1 mM dithiothreitol, pH 8.2 or 6.8 (as indicated), 10 mM magne­
sium acetate, 200 ^M CaCl2, 25 ^M phosphorylase b or 250 ^M peptide 
substrate (as indicated), 100 ng of phosphorylase kinase, and 1 mM 
[y-32P]ATP (300 cpm/pmol; DuPont NeN). The reaction mixtures were 
preincubated for 5 min at 30 °C before the reactions were started by the 
addition of ATP. Aliquots of 10 or 20 ^l of each reaction were removed 
after 5 and 15 min and spotted on Whatman 3MM or P81 filter paper 
squares. Whatman 3MM paper squares were used for the protein sub­
strate, and P81 filter paper squares were used for the synthetic peptide 
substrate. The paper squares were immediately placed in 10% trichlo­
roacetic acid, 4% sodium pyrophosphate (3MM paper) or 75 mM H3PO4 
(P81 paper). The papers were washed at least three times, rinsed in 
95% ethanol, dried, and counted in a scintillation counter following the 
addition of Opti-fluor (Packard Instrument Co.) scintillation mixture. 
Assays containing antibodies or Fab fragments were performed as 
described above except that the enzyme was preincubated on ice (in a 
volume of 10 ^l) with the indicated concentrations of antibody or Fab 
fragment for the indicated times before addition to the protein kinase 
reaction mixture.
cAMP-dependent Protein Kinase Activation—Phosphorylase kinase 
(2 mg/ml) was activated by incubation with 0.02 milliunits of cAMP-de­
pendent protein kinase catalytic subunit (Promega; units of activity are 
as defined by Promega) and 1 mM ATP for 30 min in a volume of 100 ^l 
in the presence of the pH 6.8 kinase assay buffer described above. The 
protein kinase-activated phosphorylase kinase was then preincubated 
with antibody and assayed as described above.
Statistical Analysis—Error bars associated with each data set rep­
resent standard errors of the mean calculated from duplicate or tripli­
cate assay tubes, each of which was sampled at two time points. In some 
cases, the data represent means and standard errors from more than 
one experiment. Nonlinear least squares curve-fitting was performed 
using MacCurveFit (version 1.03) to estimate Km and Vmax values and 
to determine partial inhibition constants.
RESULTS
A c tiv a tio n  o f  P h o sp h o ry la se  K in a se  by A n tip e p tid e  A n tib o d ­
ies— The ability  of each affin ity-purified  an tipep tide  antibody 
to  a lte r  th e  enzym atic activ ity  of phosphorylase k inase  holoen­
zym e (Fig. 2) and  y-S complex (Fig. 3) a t pH  8.2 w as exam ined. 
Two of th e  antibodies, an ti-P hK 1 and  an ti-P hK 5, induced ac­
tiva tion  of bo th  phosphorylase k inase  and  th e  y S  complex in  
th e  presence and  absence of C a2+. In  th e  p resence of Ca2+, 
an ti-P hK 1 antibody increased  holoenzym e activ ity  by approx­
im ate ly  1150% and  th e  y S  complex activ ity  by 250%. The 
degree of holoenzym e activation  induced by an ti-P hK 5 a n ti­
body w as approxim ately  70% of th a t  seen w ith  an ti-P h K 1  a n ­
tibody and  som ew hat less (50%) for th e  y S  complex. The ex ten t
Fig. 3. Effect o f affin ity -purified  a n tip ep tid e  an tibod ies on y S  
com plex activ ity  in  th e  p resence of Ca2+ o r EGTA. The y S  com­
plex was incubated in the presence of antipeptide antibodies and as­
sayed at pH 8.2 as described under “Experimental Procedures.” The 
horizontal dashed line represents the Ca2+-stimulated activity of the 
y S  complex in the absence of antibody. Error bars represent the stand­
ard error of the mean.
of holoenzym e and  y S  complex activation  induced by an ti- 
PhK 1 in th e  presence of 3 mM EGTA w as g rea te r th a n  th a t  seen 
in  th e  presence of C a2+ w ith  no antibody p resen t. The ex ten t of 
stim u la tion  of holoenzym e and  y-S complex activ ity  by an ti- 
PhK 5 in th e  presence of 3 mM EGTA w as nearly  equal to th e  
C a2+-s tim u la ted  activ ity  in  th e  absence of antibody. The con­
cen tra tion  of anti-PhK 1 requ ired  for activation  w as com parable 
for th e  holoenzym e and  th e  y-S complex, in  th e  p resence or 
absence of C a2+, w ith  m axim al activation  occurring a t an  a n ­
tibody concentration  of 0.3 mg/ml (data  not shown).
To determ ine w h eth er th e  activation  of phosphorylase k i­
n ase  by anti-PhK 1 requ ired  antibody w ith  in tac t Fc regions, 
Fab  fragm ents of anti-PhK 1 w ere te s ted  for th e ir  ab ility  to 
ac tiva te  th e  holoenzym e and  th e  y-S complex. O ther an tip ep ­
tide  antibodies w ere not investiga ted  due to difficulties in  p u ­
rifying these  o ther antibodies in  sufficient q u an titie s  to  conduct 
such stud ies. The anti-PhK 1 Fab  fragm en ts w ere unab le  to 
ac tiva te  e ith e r th e  holoenzym e or th e  y-S complex (Fig. 4). A 
sandw ich ELISA  w as used  to determ ine  w h e th e r th e  inab ility  
of th e  Fab fragm en ts to ac tiva te  w as due to th e  loss of b inding 
capability. I t w as found th a t  th e  anti-PhK 1 Fab  fragm ents 
w ere still able to b ind  holoenzym e and  th e  y-S complex as 
tigh tly  as th e  in tac t antibody (Fig. 5).
The tim e dependence of antibody activation  w as assessed  by 
m easu ring  holoenzym e and  y-S complex activ ity  afte r overnight 
and  1-h incubations. A ntibody-induced activation  by anti-PhK 5 
occurred in  a tim e-dependen t m an n e r w ith  holoenzym e b u t not 
w ith  th e  y-S complex (data  no t shown). A nti-PhK 1 exhibited  no 
difference betw een  th e  overnight and  1 -h incubations in  th e  
ex ten t of activation  of e ith e r holoenzym e or th e  y-S complex.
To exam ine th e  possible m echanism s for antibody-induced 
activation , k inetic  analyses w ere perform ed w ith  anti-PhK 1 
and  anti-PhK 5 antibody using  bo th  th e  holoenzym e and  th e  y-S 
complex in  th e  p resence and  absence of C a2+ a t pH  6 .8 . The K m 
and  V max values determ ined  from  these  analyses are  show n in 
Table I. In  th e  presence of C a2+, th e  effects of bo th  anti-PhK 1 
and  anti-PhK 5 on holoenzym e activ ity  w ere p rim arily  a tt r ib ­
u tab le  to changes in  V max, w ith  only m odest or m in im al effects 
on K m values for ATP or phosphorylase b. B ecause of th e  
in trin sic  difficulty in  accurately  determ in ing  K m values, it is 
difficult to know  w h e th e r th e  2-fold decrease in  K m value for 
ATP seen w ith  anti-PhK 1 and  th e  com parable effect of an ti- 
PhK 5 on th e  K m value for phosphorylase b a re  due to norm al 
assay  variab ility  or w h eth er th ese  low er K m  values reflect real 
b u t m odest effects of these  antibodies on enzym e-substra te  























Fig. 4. A ctivity of phosphory lase k inase  holoenzym e and  the  
y S  com plex in  th e  p resence of Fab fragm en ts of an ti-P hK l.
Phosphorylase kinase holoenzyme (A) or the yS complex (B) were pre­
incubated with affinity-purified anti-PhK1 antibody or anti-PhK1 Fab 
fragments in the presence of Ca2+ (1 mM) or EGTA (3 mM) and then 
assayed a t pH 8.2 as described under “Experimental Procedures.” Error 
bars represent the standard error of the mean from three independent 
assays (each performed in duplicate). The horizontal dashed line rep­
resents Ca2+-stimulated enzyme activity in the absence of antibody.
oenzyme Vmax values w ere m uch m ore robust, w ith  anti-PhK 1 
increasing  Vmax values 10-13-fo ld  and  anti-PhK 5 increasing  
Vmax values 7-9-fold.
S ligh tly  d ifferent k inetic  p a tte rn s  w ere observed for holoen- 
zym e activation  w hen  th e  C a2+ concentration  w as low ered 
using  EGTA, a lthough  th e  effect of antibody w as still predom ­
inan tly  a V max effect. A ssays of th e  holoenzym e w ith  vary ing  
concentrations of phosphorylase b  in  th e  presence of 3 mM 
EGTA resu lted  in  a 9.3-fold increase  in  Vmax w ith  anti-PhK 1 
antibody b u t an  increase  of only 3.2-fold w ith  anti-PhK 5 a n ti­
body (Table I). T here w ere also 4-fold and  2.4-fold decreases in 
th e  K m va lue  for phosphorylase b  w ith  an ti-P h K 1  an tibody and 
anti-PhK 5 antibody, respectively. K inetic analyses using  ATP 
as th e  varied  su b s tra te  ind icated  th e re  w ere no significant 
differences in  K m va lues for ATP, b u t th e re  w ere 22.5- and 
7-fold increases in  V max values w ith  anti-PhK 1 and  an ti-PhK 5 
antibodies, respectively. These observations ind icate  th a t in 
th e  absence of C a2+, anti-PhK 1 and  anti-PhK 5 bo th  activa te  
th e  holoenzym e th rough  a m ixed type m echanism , w hich is 
m ostly due to an  effect on V max, b u t w ith  som e ra te-enhancing  
effects on th e  K m  for phosphorylase b  and  no effect on th e  K m 
for ATP.
T he k inetic  p a tte rn s  observed for ac tivation  of th e  yS  com­
plex by anti-PhK 1 and  anti-PhK 5 w ere s im ila r overall to those 
seen w ith  th e  holoenzym e, w ith  ac tivation  being predom i­
n an tly  a Vmax effect (Table I). D ifferences betw een  holoenzym e 
activation  and  y S  complex activation  w ere p rim arily  seen  in 
th e  ex ten t of ac tivation  and  th e  som ew hat m ore complex p a t­
te rn  of y S  complex activation  observed w ith  anti-PhK 1 in  th e  
p resence of C a2+. A 4-fold decrease in  th e  K m va lue  for phos- 
phorylase b  and  a 2-fold increase  in  th e  V max w as seen w hen 
th e  y S  complex w as assayed  w ith  anti-PhK 1 antibody in  th e  
p resence of C a2+, ind ica ting  a m ixed type activation , w hich 
differs from  th e  p u re  V max effect seen  w ith  th e  holoenzym e. A
Fig. 5. B inding of an ti-P hK l an tibody  ( f il le d  sym bols)  an d  an- 
ti-P hK l Fab fragm ents (open sym bols) to phosphory lase k inase 
holoenzym e an d  th e  y S  com plex as de te rm ined  by sandw ich 
ELISA. Data obtained using anti-PhK1 antibody are represented by 
filled symbols, and anti-PhK1 Fab data are represented by open sym ­
bols. Data obtained using holoenzyme are depicted by square symbols, 
while those obtained using the yS  complex are represented by circles. 
Details of the sandwich ELISA are described under “Experimental 
Procedures.” Each point represents the mean of three independent 
assays (each with quadruplicate wells) ± S.D.
1.7-fold increase  in  Vmax w as seen w ith  th e  anti-P hK 5 a n ti­
body, w ith  no significant change in  K m for phosphorylase b . 
W ith  reg a rd  to ATP, th e re  w as no significant change in  K m 
value  observed w ith  anti-PhK 1 and  a 2-fold increase  w ith  anti- 
PhK 5, w hereas th e  Vmax value  increased  3- and  1.7-fold w ith  
anti-PhK 1 and  anti-PhK 5, respectively. The effects of anti- 
PhK 1 and  anti-PhK 5 on th e  K m and  Vmax values of th e  ySm uidx •
complex in  th e  presence of EGTA w ere qualita tive ly  th e  sam e 
as those seen in  th e  presence of C a2+, w ith  Vmax effects alw ays 
being  observed and  K m effects being seen to a variab le  degree.
Phosphorylase k inase  is ac tiva ted  by cA M P-dependent pro­
te in  k inase-catalyzed  phosphorylation  of its  a- and  0 -subunits . 
In  o rder to determ ine  if  ac tivation  by phosphory lation  affects 
th e  ac tivation  induced by th e  anti-PhK 1 and  anti-PhK 5, a n ti­
body ac tivation  assays w ere perform ed using  holoenzym e acti­
v a ted  by cA M P-dependent p ro te in  k inase  (Fig. 6 ). A ctivation by 
cA M P-dependent p ro te in  k inase  re su lted  in  a 4-fold s tim u la ­
tion  of activity , w hich is com parable w ith  th e  3.8-fold s tim u la ­
tion  in  Vmax induced by ra is in g  th e  pH  from 6.8 to 8.2 w ith  th is  
p rep a ra tio n  of phosphory lase k inase  (da ta  not shown). The 
activation  induced e ith e r by anti-PhK 1 (13-fold) or by anti- 
PhK 5 (8-fold) w as significantly  g re a te r  th a n  th e  ac tivation  seen 
w ith  cA M P-dependent p ro te in  k inase. In teresting ly , cAMP-de­
penden t p ro te in  k inase  ac tivation  of phosphory lase k inase 
com pletely blocked subsequen t ac tivation  of th e  holoenzym e by 
e ith e r antibody (Fig. 6).
In h ib it io n  o f  P h o sp h o ry la se  K in a se  A c tiv i ty  by A n tip e p tid e  
A n tib o d ie s— In  con trast to th e  activation  seen  w ith  anti-PhK 1 
and  anti-PhK 5, bo th  anti-P hK 9 and  anti-PhK 13 caused inh ib i­
tion  of holoenzym e and  y S  complex activ ity  (Figs. 2 and  3; 
Table I). Inh ib ition  of holoenzym e activ ity  by anti-PhK 9 w as 
m odest (2 0 %) and  m axim al a fte r  1  h  of incubation  (da ta  not 























Sum m ary o f kinetic data for antibody activation and inhibition o f holoenzyme and y-S complex activity 
Vmax and K m values for ATP and phosphorylase b a t pH 6.8 were determined by nonlinear curve fitting of initial rate data using MacCurveFit 
(version 1.03). The errors associated with each value are 95% confidence intervals. Values in parentheses were determined from linear regression 
of double reciprocal plots. Initial rates were determined as described under “Experimental Procedures” using phosphorylase b concentrations 
varying from 10 to 100 xM at a fixed concentration of ATP (1 mM) and ATP concentrations ranging from 0.25 to 1 mM at a fixed concentration of 
phosphorylase b (25 xm). All experiments were done in duplicate at two time points and repeated a t least three times. Control reactions were 
handled in the same manner as those with antibody, except that no antibody was added.
Phosphorylase b ATP
Km Vmax Km Vmax
xM xm o l/m in /m g xM x m o l/m in /m g
Phosphorylase kinase holoenzyme in the presence of Ca2+ (1 mM)
Control 64.0 ± 3.16(53.2) 2.23 ± 0.05(2.01) 0.25 :t 0.03 (0.33) 1.37 ± 0.06 (1.55)
Anti-PhK1 55.8 ± 8.11(55.9) 28.8 ± 1.96 (28.9) 0.13 :t 0.01 (0.2 1 ) 13.9 ± 0.04 (15.7)
Anti-PhK5 32.7 ± 7.51(38.6) 14.8 ± 1.26(15.9) 0.26 :t 0.01 (0.25) 12.7 ± 0.24 (12.6)
Anti-PhK13 65.9 ± 13.8(53.3) 1.34 ± 0.14 (1.20) 0.31 :t 0.05 (0.48) 0.79 ± 0.05(0.96)
Phosphorylase kinase holoenzymet in the absence of Ca2+ (3 mM EGTA)
Control 69.0 ± 11.2 (49.7) 0.49 ± 0.04(0.61) 0.19 :t 0.06 (0.17) 0.39 ± 0.04(0.38)
Anti-PhK1 17.5 ± 10.1(23.1) 4.56 ± 0.77 (5.04) 0.45 :t 0.05 (0.73) 8.79 ± 0.46 (11.4)
Anti-PhK5 28.9 ± 10.2 (24.2) 1.57 ± 0.20 (1.50) 0.42 :t 0.06 (0.50) 2.70 ± 0.15 (2.94)
y-S complex in the presence of Ca 2+ (1 mM)
Control 47.9 ± 9.57(31.5) 1.76 ± 0.15 (1.46) 0.13 :t 0.02 (0.15) 1.02 ± 0.03 (1.06)
Anti-PhK1 12.5 ± 3.00(17.0) 3.81 ± 0.22 (4.13) 0.10 :t 0.01 (0.09) 3.00 ± 0.06 (2.94)
Anti-PhK5 31.2 ± 11.2 (38.5) 2.94 ± 0.38 (3.17) 0.27 :t 0.05 (0.27) 1.71 ± 0.11 (1.72)
y-S complex in the absence of Ca2+ (3 mM EGTA)
Control 59.5 ± 9.37(72.4) 0.41 ± 0.03 (0.45) 0.21 ±: 0.04 (0.27) 0.37 ± 0.02 (0.41)
Anti-PhK1 16.7 ± 5.25(26.2) 1.43 ± 0.12 (1.65) 0.14 :t 0.01 (0.15) 1.49 ± 0.03 (1.52)
Anti-PhK5 85.2 ± 26.9 (96.9) 2.06 ± 0.36 (2.16) 0 .11  :t 0.02 (0.12 ) 0.75 ± 0.03 (0.78)
Fig. 6. A ctivity  of cA M P-dependent p ro te in  k inase-ac tiva ted  
phosphory lase k inase  holoenzym e in  th e  p resence  of anti-PhK 1 
and  anti-PhK 5 antibody. Phosphorylase kinase was activated by 
cAMP-dependent protein kinase and then incubated with or without 
anti-PhK1 or anti-PhK5 antibody, as indicated, before assaying for 
activity a t pH 6.8. Conditions used for activation and for the phospho­
rylase kinase assay are described under “Experimental Procedures.” 
Error bars represent the standard error of the mean of three independ­
ent assays (each performed in duplicate).
nounced b u t slower, w ith  less th a n  20% inh ib ition  occurring 
a fte r 1 h  and  —50% inh ib ition  being reached  a fte r  24 h  (data  
not shown). W hen e ith e r  anti-P hK 9 or anti-PhK 13 w as incu­
ba ted  w ith  th e  yS  complex, a rela tively  slow onset of inh ib ition  
w as observed (da ta  not shown). A fter a  1-h incubation  of th e  yS  
complex w ith  anti-PhK 9 antibody th e re  w as only sligh t inh ib i­
tion (—10%), w hereas anti-PhK 13 elicited nearly  com plete in ­
hib ition  (90%) a fte r  1-h. B oth anti-P hK 9 and  anti-PhK 13 
caused nearly  com plete inh ib ition  (98%) of yS  complex activ ity  
w ith  overnight incubation.
K inetic stud ies of anti-PhK 13 inh ib ition  of holoenzym e ac­
tiv ity  ind icate  a noncom petitive mode of inh ib ition  w ith  a 1.7- 
fold decrease in  V max value  and  little  or no effect on th e  K muidx m
value  for e ith e r ATP or phosphorylase b (Table I). Inh ib ition  of 
holoenzym e by anti-PhK 13 w as concentration-dependent and  
sa tu rab le  (Fig. 7). W ith  s a tu ra tin g  concentrations of anti- 
PhK 13, only a p a rtia l (—50%) inh ib ition  of th e  holoenzym e w as
0.1 0.2 0.3 0.4 0.5 
Anti-PhK13 Concentration (mg/ml)
Fig. 7. C oncen tra tion  dependence of phosphory lase k inase 
holoenzym e activ ity  by  affin ity -purified  anti-PhK 13 antibody.
Phosphorylase kinase holoenzyme was incubated overnight with the 
indicated concentrations of anti-PhK13 antibody and then assayed at 
pH 8.2 as described under “Experimental Procedures.” The data were fit 
to the equation for partial noncompetitive inhibition (Fig. 8). The curve 
shown was calculated using the equation shown in Fig. 8 and the best 
fit values determined by MacCurveFit (version 1.03). Each point rep­
resents the mean of three independent assays (each performed in du­
plicate) ± the standard error of the mean.
obtained (Fig. 7), w hereas essen tia lly  com plete inh ib ition  (99%) 
w as seen w ith  th e  y S  complex (Fig. 3). T hus, anti-PhK 13 acts 
as a p a r tia l inh ib ito r of th e  holoenzym e (25) b u t a  full inh ib ito r 
of th e  y S  complex. A kinetic  schem e illu s tra tin g  p a rtia l non­
com petitive inh ib ition  of holoenzym e activ ity  as seen w ith  anti- 
PhK 13 is depicted in  Fig. 8 . F o r th e  sake of sim plicity, only one 
su b s tra te  is shown. In  th is  schem e, anti-PhK 13 antibody is 
rep resen ted  as I , w hich is able to b ind  free enzym e (E ) as well 
as th e  enzym e-substra te  complex (ES). Inh ib ito r bind ing  to th e  
enzym e has no effect on su b s tra te  b ind ing  (K s), and  conversely, 
su b s tra te  b ind ing  has no effect on inh ib ito r b ind ing  (Ki). The 
cata ly tic efficiency of th e  enzym e-substra te-inh ib ito r complex 
(E S I), is reduced  re la tive  to th e  enzym e-substra te  complex, and  






















Fig. 8. K inetic schem e and  equa tion  for p a rtia l noncom peti­
tive inh ib ition  of phosphory lase k inase  holoenzym e activ ity  by 
an ti-PhK l3  antibody. [S] is the concentration of phosphorylase b; Ks 
is the Michaelis constant for phosphorylase b; v/Vmax is the fractional 
activity; [I ] is the concentration of anti-PhK13 antibody; Ki is the 
inhibition constant (in mg/ml); and a is the partial inhibition coefficient. 
For the sake of simplicity and because anti-PhK13 had no effect on the 
Km for ATP, the kinetic scheme and equation do not include the sub­
strate, ATP. The values for a and Ki were determined by nonlinear 
curve fitting of the data in Fig. 7 using MacCurveFit (version 1.03).
In  th e  case of p u re  noncom petitive inhib ition , a  = 0. E stim ates  
of a  (0.589 ±  0.028) and  K t (0.035 ±  0.014 mg/ml) w ere d e te r­
m ined for anti-PhK 13 from n on linear leas t squares curve fit­
ting  of th e  d a ta  in  Fig. 7 u sing  th e  equation  show n in  Fig. 8 . 
The curve calcu lated  using  these  b e s t fit va lues is p lo tted  in 
Fig. 7.
B ecause it h as  recently  been show n th a t th e  pseudosub- 
s tra te /au to inh ib ito ry  dom ain of th e  7 -subun it is ra th e r  ex ten ­
sive and  involves th e  regions corresponding to bo th  PhK 5 and  
PhK 13 (6 , 10), it w as im p o rtan t to determ ine w h e th e r using  a 
m in im al leng th  phosphate-acceptor su b s tra te  m igh t have any 
effect on antibody-induced ac tivation  or inhibition . Fig. 9 shows 
th e  re su lts  of assays perform ed in  th e  p resence of anti-PhK 1, 
anti-PhK 5, and  anti-PhK 13 using  a te trad ecap ep tid e  pep tide 
su b s tra te  corresponding to th e  phosphory lation  site  of phos- 
phorylase b in  com parison w ith  phosphorylase b as substra te . 
T here  w as no difference in  th e  ac tivation  or inh ib ition  observed 
betw een  th e  two su b s tra te s , using  e ith e r phosphorylase k inase  
holoenzym e or th e  y S  complex, w ith  reg a rd  to any of th e  th ree  
an tibodies exam ined.
DISCUSSION
T he purpose of th is  study  w as to characterize  monospecific 
an tibodies ra ised  ag a in s t pep tides spann ing  th e  regu la to ry  
dom ain of th e  7 -subun it of phosphorylase k inase  to determ ine  
w hether any of th ese  an tibodies m igh t have an  effect on th e  
biochem ical p roperties of th e  enzym e. A ntipep tide antibodies 
have previously been  used  to identify  im p o rtan t functional 
dom ains in  o ther p ro te in  k inases  by characteriz ing  th e  effects 
of antibody b ind ing  on enzym e activation  and  inh ib ition  ( 1 2 ­
17). A ntibodies capable of ac tiva ting  or inh ib iting  phosphoryl- 
ase k in ase  have also been  ra ised  using  na tive  phosphorylase 
k inase  holoenzym e and  d en a tu red  sub u n its  of phosphorylase 
k inase  as an tigens (26-28). H owever, m ost of th e  epitopes of 
th ese  an tiphosphory lase  k inase  an tibodies have no t been  p re ­
cisely localized, so th a t it is difficult to in te rp re t th e  effects of 
th ese  antibodies in  te rm s of th e ir  b ind ing  to specific s tru c tu ra l 
e lem ents w ith in  th e  holoenzym e. In  th e  p resen t study, th e  
effects of each antibody on enzym atic activ ity  can be in te r ­
p re ted  in  te rm s of th a t  antibody’s b ind ing  to a specific region on 
th e  regu la to ry  dom ain  of th e  7-subun it, since th e  antibody’s 
epitope is defined by th e  pep tide an tigen  used  in  ra is ing  it.
B ecause of th e  complex su b u n it s tru c tu re  and  enzymology of 
phosphorylase k inase, th e  effects of each regu la to ry  dom ain 
antibody w ere determ ined  using  two different cataly tic form s of
Fig. 9. A ntibody ac tiva tion  an d  in h ib ition  of phosphorylase 
k inase  holoenzym e an d  y S  com plex w ith  phosphory lase b o r 
syn thetic  pep tide  substra te . Phosphorylase kinase (A) or the 7S
complex (B ) was assayed a t pH 8.2 following incubation with anti- 
PhK1, anti-PhK5, or anti-PhK13 antibody and using either phospho- 
rylase b (filled bars) or peptide substrate (open bars) in the presence or 
absence of Ca2+ as indicated. Conditions of the assay are described 
under “Experimental Procedures.” Error bars represent the standard 
error of the mean of three independent assays (each performed in 
duplicate).
th e  enzym e, th e  holoenzym e and  th e  y S  complex. The form er 
cata ly tic form contains a full com plem ent of subun its , w hereas 
th e  la t te r  cata ly tic  form  lacks th e  regu la to ry  a- and  0 -subunits . 
All of th e  7 -subun it regu la to ry  dom ain an tipep tide  antibodies 
w ere found to have some sort of effect on th e  enzym atic activity  
of phosphorylase k inase, w ith  th e  C -term inal regu la to ry  do­
m ain  antibodies (anti-PhK 1 and  anti-PhK 5) s tim u la tin g  activ­
ity  and  th e  antibodies ra ised  ag a in s t th e  N -term ina l region of 
th e  regu la to ry  dom ain (anti-PhK 9 and  anti-PhK 13) being 
inhibitory.
The ac tiva ting  effects of th e  two antibodies specific for th e  C 
te rm in u s of th e  regu la to ry  dom ain of th e  7-subun it, anti-PhK 1 
and  anti-PhK 5, w ere qualita tive ly  th e  sam e in  nearly  every 
respect. B oth  w ere able to stim u la te  th e  activ ity  of holoenzym e 
and  y S  complex in  th e  p resence and  absence of C a2+ (Figs. 2 
and  3), w ith  anti-PhK 1 consistently  hav ing  th e  g re a te r  effect. 
C alcium  ion w as requ ired  for m axim al antibody ac tivation  w ith  
bo th  antibodies, regard less of w hich enzym atic form  of phos- 
phory lase k in ase  w as used. In  th e  absence of C a2+, bo th  a n ti­
bodies w ere able to stim u la te  enzym atic activ ity  to levels com­
parab le  w ith  th a t  seen w ith  C a2+ in  th e  absence of antibody. 
These d a ta  suggest th a t  anti-PhK 1 and  anti-PhK 5 affect th e  
activ ity  of phosphorylase k inase  th rough  a s im ila r m echanism  
th a t  involves a conform ational change w ith in  th e  regulatory  
dom ain of th e  7 -subunit. S ince th e  region corresponding to 
PhK 5 is th o ugh t to serve as a calm odulin-binding subdom ain 






















it seem s likely th a t  antibody-induced s tru c tu ra l changes th a t  
overcome th e  inh ib ito ry  capacity  of th e  PhK 5 region are  re ­
sponsible for ac tiva ting  phosphorylase k inase . In te resting ly , 
the  region corresponding to PhK 1 appears  to have no m easu r­
able calm odulin-binding activ ity  or p seudosubstra te-like  activ­
ity  (9, 10). However, it  is no t difficult to im agine th a t  anti-PhK 1 
b ind ing  to th e  y -subun it m igh t be capable of inducing s tru c ­
tu ra l changes in  th e  proxim al PhK 5 region (cf. Fig. 1). The 
g rea te r effects of an ti-P h K 1  com pared w ith  anti-PhK 5 are  dif­
ficult to exp lain  except th a t  p erhaps an ti-P h K 1  b ind ing  induces 
la rg er s tru c tu ra l changes in  th e  regu la to ry  dom ain th a n  the 
b ind ing  of anti-PhK 5. The effects of anti-PhK 1 and  anti-PhK 5 
on cataly tic activ ity  w ere predom inan tly  or en tire ly  th rough  an 
effect on V max, a lthough  some ra te -enhanc ing  effects on th e  K m 
for phosphorylase b w ere also seen w ith  anti-PhK 1, p a rticu ­
larly  w ith  th e  y-S complex (Table I). These re su lts  a re  consist­
en t w ith  th e  d a ta  of N ew sholm e and  W alsh  (29), w hich showed 
th a t  activation  of phosphorylase k inase  a t pH  6.8 by C a2+ and  
by phosphory lation  of th e  a- an d  ^ -subun its  w as p redom inantly  
due to changes in  Vmax. I t is in te re s tin g  to note th a t  Jen n issen  
e t a l. (28) also observed activation  of th e  holoenzym e th rough  a 
V max m echanism  w ith  antibodies ra ised  ag a in s t purified  y - and  
^ -subun its  of phosphorylase k inase. The epitopes of these  poly­
clonal antibodies w ere no t determ ined.
The degree to w hich th e  C -term inal region of th e  y -subun it 
regu la to ry  dom ain (y342-386) in te rac ts  w ith  th e  a- and  0-sub­
u n its  can  be in ferred  from  differences in  ac tiva tion  seen be­
tw een  th e  holoenzym e and  th e  y-S complex and  th e  effects of a- 
and  ^ -su b u n it phosphorylation  on antibody-induced activation. 
The m ost obvious difference betw een  antibody-induced ac tiva­
tion  of holoenzym e versu s y-S complex is th a t  th e  m agn itude  of 
activation  observed w ith  holoenzym e is generally  severalfold 
g rea te r th a n  th a t  seen w ith  th e  y-S complex (Table I). One 
possibility  for th is  difference is th a t  in  th e  nonactiva ted  holoen- 
zyme, th e  a- an d  ^ -subun its  a re  acting  to suppress activ ity  and  
th a t  anti-PhK 1 and  anti-PhK 5 relieve th is  supression. Indeed, 
it  is generally  th o u g h t th a t  th e  a- and  ^ -subun its  a re  inh ib i­
tory, since th e ir  dissociation, phosphorylation , or proteolysis 
re su lts  in  enzym e activation  (review ed in  Ref. 1). Phosphoryl­
ation  of the  a- and  ^ -subun its  by incubation  w ith  cAMP-de­
penden t p ro te in  k inase  and  M gATP effectively blocked a n ti­
body-induced ac tiva tion  (Fig. 6), providing add itional evidence 
th a t  th e  regions corresponding to P h K 1  and  PhK 5 are  involved 
in  a- and/or ^ -su b u n it regu la tion  of holoenzym e activity. The 
m echanism  by w hich phosphorylation  inh ib its  antibody-in­
duced activation  is p resen tly  unknow n, b u t th e re  are  two likely 
possibilities. The firs t is th a t  phosphory lation  p reven ts the 
antibodies from  b ind ing  to th e  y -subun it regu la to ry  dom ain. 
The second is th a t  p rio r phosphorylation  of th e  a- and/or 0 -sub­
u n it locks th e  y -subun it regu la to ry  dom ain  into  a conform ation 
th a t  cannot be a lte red  by antibody binding. S tud ies are  p res­
en tly  underw ay  to d is tingu ish  these  two possibilities, b u t re ­
gard less of the  m echanism  involved, these  d a ta  suggest a tig h t 
coupling of s tru c tu ra l changes in  th e  a- and/or ^ -subun its  to 
s tru c tu ra l changes in  th e  C -term inal 45 residues of the 
y-subunit.
The activation  of phosphorylase k inase  by an ti-P h K 1  ap ­
pears  to requ ire  antibody w ith  in tac t Fc dom ains based  on 
s tud ies using  Fab  fragm en ts of th is  antibody (Fig. 4). N either 
the  holoenzym e nor th e  y-S complex w ere ac tiva ted  by anti- 
PhK 1 Fab fragm ents, even though  th e  Fab  fragm ents w ere able 
to b ind  bo th  phosphorylase k inase an d  th e  y-S complex as 
show n by a sandw ich ELISA  (Fig. 5). These d a ta  suggest th a t  
b ind ing  of th e  second a rm  of an  antibody molecule to an  ad ja­
cent y -subun it regu la to ry  dom ain is requ ired  for activation. 
T hus, antibody-induced ac tiva tion  m ay be a  consequence of
bo th  a rm s of an  in tac t antibody molecule sim ultaneously  b ind ­
ing to th e  enzym e, w hich th e n  im p arts  a  leveraging action to 
th e  y -subun it regu la to ry  dom ain. I t  is in te re s tin g  to consider 
w hether some sort of m echanical activation  such as th is  m ight 
be an  im p o rtan t b u t heretofore unrecognized m echanism  for 
ac tiva ting  m uscle phosphorylase k inase in  response to con­
trac tile  activity. B ased on th e  effects of anti-PhK 1 and  anti- 
PhK 5 repo rted  here, m echanical activation  could be superim ­
posed on C a2+-induced activation , w ould be relatively  
independen t of cellu lar pH , and  w ould be blocked by phospho­
ry la tion  of th e  enzym e. We are cu rren tly  designing experi­
m en ts to te s t w h e th er m echanical activation  m igh t rep resen t 
an  im p o rtan t physiological m eans of reg u la tin g  phosphorylase 
k inase activ ity  in  m uscle. I t is no t clear w hy in tac t antibody 
should also be requ ired  for activation  of th e  y-S complex (Fig. 4), 
since th is  complex is th o u g h t to ex ist as a  sim ple heterod im er 
(30). O ne possibility is th a t  antibody b ind ing  m igh t facilita te  
th e  form ation of a (y-S)2 or (y-S)4 complex th a t  is th e n  ac tivated  
by antibody as in  the  holoenzym e complex.
In  con trast to th e  ac tiva ting  effects of an ti-P h K 1  and  anti- 
PhK 5, th e  antibodies ra ised  ag a in s t th e  N  te rm in u s of the 
y -subun it regu la to ry  dom ain exhibited  inh ib ito ry  effects on 
phosphorylase k inase  activity. The effects of an ti-PhK 9 w ere 
very w eak  w ith  reg a rd  to inh ib ition  of the  holoenzym e and  th e  
y-S complex (Figs. 2 and  3), a lthough  overnight incubation  of 
anti-PhK 9 w ith  th e  y-S complex elicited  essen tia lly  complete 
inh ib ition  (d a ta  no t shown). The antibody to PhK 13 could only 
pa rtia lly  in h ib it th e  activ ity  of th e  holoenzym e (Figs. 1, 3, and  
5) b u t w as able to com pletely in h ib it the  activ ity  of th e  y-S 
complex (Figs. 2 and  5). The differences in  inh ib ition  w ith  
respect to phosphorylase k inase  holoenzym e and  the  y-S com­
plex are  m ost likely due to th e  presence of th e  a- and  0-sub­
u n its  in  th e  holoenzym e, w hich m ay in te rfe re  w ith  th e  ability  of 
these  antibodies to elicit complete inhibition.
T here are  a t  le a s t two m echanism s by w hich an ti-P hK 9 and  
anti-PhK 13 m igh t in h ib it th e  activ ity  of phosphorylase kinase. 
The firs t possibility  is th a t  these  antibodies m igh t tra p  the 
regu la to ry  dom ain in  a conform ational s ta te  th a t  p reven ts ac­
tivation . T his seem s a likely possibility , since PhK 13 is though t 
to function  as bo th  a calm odulin-binding subdom ain  (9) and  as 
an  au to inh ib ito ry /pseudosubstra te  subdom ain  (10). M oreover, 
th is  m echanism  of antibody-induced inh ib ition  h as previously 
been  show n to operate  in  th e  case of try p to p h an  syn thase , 
w here an  antibody to th e  p2-subun it p reven ted  or res tric ted  
m olecular m ovem ents associated  w ith  su b s tra te  b ind ing  d u r­
ing th e  cataly tic cycle (31). A n a lte rn a tiv e  exp lana tion  for in ­
h ib ition  by anti-PhK 9 and  anti-PhK 13 is th a t  antibody b ind ing  
to th e  N -term ina l region of th e  regu la to ry  dom ain causes steric 
h indrance  of th e  catalytic site. K inetic analysis of anti-PhK 13 
inh ib ition  should m ake it  possible to d is tingu ish  betw een  these 
two a lte rn a tiv e  m echanism s. Steric h indrance  w ould be ex­
pected to re su lt in  a change in  K m for phosphorylase b , w hereas 
a  m echanism  involving res tric tio n  of conform ational changes 
w ould be p red icted  to cause a reduction  in  Vmax. The k inetic 
d a ta  obtained  for anti-PhK 13 (Table I) a re  consisten t w ith  th is  
antibody acting  th rough  a m echanism  th a t  re s tr ic ts  conform a­
tional changes in  th e  regu la to ry  dom ain, since anti-PhK 13 
acted  as a noncom petitive inh ib ito r of phosphorylase k inase 
activity. I f  th e  m echanism  of inh ib ition  by an ti-PhK 13 w ere to 
involve steric  h indrance  of th e  p ro te in  su b s tra te , th e n  th e  use 
of a  sm aller phosphate-accep tor su b s tra te  m igh t a t  le a s t p a r­
tia lly  allev iate  th e  inh ib ito ry  effects of th e  antibody. However, 
th e  use of a  te tradecapep tide  phosphate-acceptor su b s tra te  
in s tead  of phosphorylase b h ad  no effect on th e  efficacy of 
anti-PhK 13 w ith  reg a rd  to e ith e r holoenzym e or y-S inh ib ition  























acts by p reven ting  conform ational changes in  th e  y-subunit 
regu la to ry  dom ain im p o rtan t for full cataly tic efficiency. I t is 
w orth  no ting  th a t  a  y -subun it monoclonal antibody whose 
epitope h as been  iden tified  as being ju s t  N -term ina l to PhK13 
(residues 277-290) ac tiva tes th e  holoenzym e approxim ately  
2-fold a t  pH  6.8 (32).2 T his region of th e  y -subun it is th o u g h t to 
be a  linker region betw een  the  cataly tic and  regu la to ry  do­
m ains. The k inetic m echanism  of th e  activation  by th is  a n ti­
body is no t yet know n, b u t it  is in te re s tin g  th a t  it  b inds closely 
to w here anti-PhK 13 binds b u t elicits an  opposite effect on 
activity.
E xperim en ts com paring th e  effect of incubation  tim e on an ­
tibody-induced activation  an d  inh ib ition  (d a ta  no t shown) sug­
gest th a t  ce rta in  conform ational s ta te s  in  phosphorylase k i­
nase  a re  re la tively  slow to form. In  th e  case of anti-PhK 5, 
significantly  g rea te r activation  o fth e  holoenzym e w as observed 
a fte r 2 4  h  of incubation  w ith  th e  antibody th a n  a fte r a  1 -h 
incubation . T his effect appeared  to be dependen t upon the 
presence of th e  a- and/or ^ -subun its , since no such tim e-de­
penden t effect w as observed for anti-PhK 5 w ith  th e  y S  com­
plex. Proteolysis of th e  a- and/or ^ -subun its  is know n to re su lt 
in  activation  of th e  holoenzym e (review ed in  Ref. 1), b u t th is  is 
unlikely  to be th e  m echanism  for slow activa tion  w ith  anti- 
PhK 5, since no significant tim e-dependent activation  w as seen 
w ith  th e  control incubation  or w ith  th e  o ther antibodies. M ore­
over, inh ib ition  of holoenzym e by anti-PhK 13 w as also m ark ­
edly tim e-dependent, as w as inh ib ition  of the  y S  complex by 
anti-PhK 9. The slow ra te s  of activation  an d  inh ib ition  noted  
above are  unlikely  to be due to diffusional effects, since an 
equilib rium  betw een  bound  and  free antibody should be 
reached  in  well u n d er an  hour w ith  th e  concentrations of a n ti­
body an d  enzym e used  in  the  incubations. The fact th a t  differ­
en t tim e-dependen t effects w ere observed w ith  d ifferent form s 
of phosphorylase k inase  also argues ag a in s t slow diffusional 
effects being the  reason  for slow activation  or inhibition . One 
possible m echanism  to exp lain  th e  delayed effects of antibody 
on cataly tic activ ity  is th a t  th e  enzym e m ay need  to undergo a 
slow conform ational change before antibody can bind. A nother 
possibility  is th a t  th e  enzym e undergoes a  slow conform ational 
change a fte r antibody is bound. A th ird  possibility  is th a t  slow- 
acting  antibodies are  only able to b ind  to a  very in frequen t or 
low probability  conform ational s ta te  in  a highly mobile region 
of the  enzym e. A t p resen t, we are  unab le  to d is tingu ish  am ong 
these  several m echanism s. H owever, because g rad u a l changes 
in  phosphorylase k inase  cataly tic activ ity  could have im p o rtan t 
physiological consequences, it  w ill be im p o rtan t to characterize  
the  underly ing  m echanism s in  fu tu re  s tud ies and  to determ ine 
w h eth er they  are  operative in  s itu .
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Note A dded in Proof-—It has come to our attention that the idea for 
the possibility of the mechanical activation of phosphorylase kinase 
linked to muscle contraction has been independently proposed by Dr. 
Gerald M. Carlson and co-workers of the University of Tennessee, 
Memphis based on structural studies that localized a region of the 
enzyme’s inhibitory ^-subunits to near the contact points between 
dimers in the tetrahedral dimer ofdimers, which describes the holoen- 
zyme. It was hypothesized that slight mechanical rotation of the lobes 
could activate the enzyme by mimicking the structural changes that 
typically occur when tetrahedral dimers of dimers undergo T to R 
transitions in response to ligands.
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